Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy

Biochemistry, Genetics and Molecular Biology

• Dendritic Cell 100%
• Cancer Immunotherapy 100%
• Capsid 100%
• Transgene 100%
• Monocyte 100%
• Prostate-Specific Antigen 75%
• Wild Type 75%
• Promoter Region 75%
• Development 50%
• Adeno Associated Virus Vector 50%
• CD11c 50%
• Surface Property 25%
• Mutant 25%
• Drive 25%
• Serine 25%
• Threonine 25%
• Adeno Associated Virus 25%
• Enhancer Region 25%
• Antigen Specificity 25%
• Serotype 25%
• Regulatory Element 25%
• Cell Clone 25%
• Site-Directed Mutagenesis 25%
• LNCaP 25%
• Expression Cassette 25%
• Simian Virus 40 25%
• Simian Virus 25%

Immunology and Microbiology

• Dendritic Cell 100%
• Capsid 100%
• Cancer Immunotherapy 100%
• Monocyte 100%
• Transgene 100%
• Prostate Specific Antigen 75%
• Wild Type 75%
• Promoter Region 75%
• Development 50%
• Adeno Associated Virus Vector 50%
• Cytotoxic T Cell 50%
• CD11c 50%
• Mutant 25%
• Surface Property 25%
• Cells 25%
• Immunotherapy 25%
• Adeno Associated Virus 25%
• Site Directed Mutagenesis 25%
• Serotype 25%
• Cell Clone 25%
• Enhancer Region 25%
• Simian Virus 25%
• Tumor Vaccine 25%
• Simian Virus 40 25%
• Tumor Antigen 25%
• Adeno-Associated Virus 25%

Medicine and Dentistry

• Virus Capsid 100%
• Dendritic Cell 100%
• Cancer Immunotherapy 100%
• Transgene 100%
• Monocyte 100%
• Promoter Region 75%
• Prostate Specific Antigen 75%
• Development 50%
• Cytotoxic T-Cell 50%
• Adeno Associated Virus Vector 50%
• Cells 25%
• Element 25%
• T Cell 25%
• Drive 25%
• Immunotherapy 25%
• Adeno-Associated Virus 25%
• Mutant 25%
• Enhancer Region 25%
• SV40 25%
• Serotype 25%
• Prostate Adenocarcinoma 25%
• Simian Virus 25%
• Serine 25%
• Tumor Antigen 25%
• Threonine 25%
• Site-Directed Mutagenesis 25%
• Tumor Vaccine 25%
• Intracellular Trafficking 25%